Sumit Chanda - Creating a Safer Future with AI Drug Discovery (EP.04)
Sumit Chanda and Daniel Haders II, Ph.D. conclude our four-part series by discussing the applications of AI drug discovery post-COVID. They hone in on the importance of using therapeutics to fill gaps in treatment, and how therapeutics discovered using this method pave the way for a safer future.
Model Medicines recently partnered with the Chanda Lab at Sanford Burnham Prebys Medical Discovery Institute to discover and develop new treatments for COVID-19 and other infectious diseases.
Sumit Chanda earned his Ph.D from Stanford University in 2001, and received his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF). He subsequently transitioned to a Group Leader position, and established his research group in the Division of Cellular Genomics at GNF. In 2007, he joined the Infectious and Inflammatory Disease Center at Sanford-Burnham Medical Research Institute as an Associate Professor. Dr. Chanda was promoted to Professor in 2013. In 2015, he was appointed Director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys Medical Discovery Institute.
